The BPC-157 and TB-500 pairing, sold under the name Wolverine, is one of the most frequently discussed combinations in recovery-focused peptide circles. What does the underlying research on each peptide actually show, separately and together?
What we know from the literature
BPC-157 is a synthetic pentadecapeptide studied largely in preclinical tendon and soft-tissue injury models, with proposed mechanisms centered on VEGFR2-mediated angiogenesis and nitric oxide signaling through the Akt-eNOS pathway (Current Reviews in Musculoskeletal Medicine, 2025). TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring protein studied for its role in cell migration and wound repair; in a rat full-thickness wound model, thymosin beta-4 increased reepithelialization and collagen deposition compared to controls (Sosne et al., J Invest Dermatol, 1999, PMID 10469335). Outcomes are individual, and both peptides’ evidence bases remain weighted toward animal and preclinical models.
Two different mechanisms aimed at a similar goal
BPC-157’s proposed activity runs primarily through angiogenesis-related signaling pathways, while TB-500’s parent molecule works through actin regulation that governs cell migration, a mechanistically distinct route to a related outcome: helping cells move into and rebuild an injured area. A broader thymosin beta-4 review describes activity across cell migration, blood vessel formation, and reduced myofibroblast-driven scarring, primarily from animal and in vitro studies with some early-phase human trials in specific indications like corneal repair (Goldstein et al., Expert Opin Biol Ther, 2012, PMID 22074294). A 2026 scoping review of the TB-500 literature specifically found the evidence base still weighted toward in vitro and animal designs, with direct human data for the synthetic 17-amino-acid TB-500 fragment limited to a single included study. Individual results vary considerably given how early-stage this evidence still is.
What combining them does and does not tell us
No published trial has evaluated BPC-157 and TB-500 administered together as a single stack. Each peptide’s supporting literature was generated independently, generally in different animal injury models. It is reasonable to describe why researchers are interested in pairing complementary mechanisms, angiogenesis alongside cell-migration support, but that interest is a hypothesis, not a demonstrated combined effect. Outcomes are individual, and stacking two compounds does not mean their separate preclinical findings simply add together in a person.
How to access it responsibly
- Everything is available after a licensed-provider evaluation.
- Peptides are compounded through a US-licensed compounding pharmacy.
Sources
- Regeneration or Risk? A Narrative Review of BPC-157. Current Reviews in Musculoskeletal Medicine, 2025 pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
- Sosne G et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-8. PMID 10469335 pubmed.ncbi.nlm.nih.gov/10469335/
- Goldstein AL et al. Thymosin beta4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012. PMID 22074294 pubmed.ncbi.nlm.nih.gov/22074294/